Early and Very Early GRIM19 and MCL1 Expression Are Correlated to Late Acquired Prednisolone Effects in a T-Cell Acute Leukemia Cell Line.
Childhood leukemia
GRIM19
Gene expression
Glucocorticoid resistance
MCL1
Prednisolone
Journal
Advances in experimental medicine and biology
ISSN: 0065-2598
Titre abrégé: Adv Exp Med Biol
Pays: United States
ID NLM: 0121103
Informations de publication
Date de publication:
2021
2021
Historique:
entrez:
13
1
2022
pubmed:
14
1
2022
medline:
15
1
2022
Statut:
ppublish
Résumé
Glucocorticoids (GCs) are still first-line drugs for the treatment of childhood acute lymphoblastic leukemia (ALL). Prednisolone is a corticosteroid and one of the most important agents in the treatment of ALL. We report here a study of Prednisolone treatment using as a model a leukemia cell line with subsequent investigation of resistance-related gene expression. Gene silencing has been used in order to identify significant targets of resistance to GC-induced apoptosis in ALL cells. We analyzed effects of increasing doses of Prednisolone on ALL cell survival and growth, and we monitored immediate effects on gene expression through gene expression assays. We determined Prednisolone cytotoxicity and cell cycle distribution as well as DNA content. Upon treatment with escalating Prednisolone concentration, we observed a gradual decline in cell survival. MCL1 and GRIM19 were investigated as possible genes for the intrinsic capacity of this cell line to respond to corticosteroid and a snapshot of early changes was examined. Early MCL1 and GRIM19 expression correlated significantly to late GC-induced apoptosis. Prednisolone competitively induces MCL1 expression. Consistently with previous studies on primary leukemia blasts, cells are sensitive to proteasome inhibitor MG132; no interference of Prednisolone with MG132 effects on this cell line was noted. The inherent plasticity of clinically evolving cancer justifies approaches to characterize and prevent undesirable activation of early oncogenic pathways. Study of the pattern of intracellular signal pathway activation by anticancer drugs can lead to development of efficient treatment strategies by reducing detrimental secondary effects.
Identifiants
pubmed: 35023102
doi: 10.1007/978-3-030-78787-5_20
doi:
Substances chimiques
MCL1 protein, human
0
Myeloid Cell Leukemia Sequence 1 Protein
0
Prednisolone
9PHQ9Y1OLM
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
147-160Informations de copyright
© 2021. The Author(s), under exclusive license to Springer Nature Switzerland AG.
Références
Lambrou GI et al (2009) Prednisolone exerts late mitogenic and biphasic effects on resistant acute lymphoblastic leukemia cells: relation to early gene expression. Leuk Res 33(12):1684–1695. https://doi.org/10.1016/j.leukres.2009.04.018
doi: 10.1016/j.leukres.2009.04.018
pubmed: 19450877
Lauten M et al (2001) Clinical outcome of patients with childhood acute lymphoblastic leukaemia and an initial leukaemic blood blast count of less than 1000 per microliter. Klin Padiatr 213(4):169–174
doi: 10.1055/s-2001-16848
Yeh JM et al (2020) Life expectancy of adult survivors of childhood cancer over 3 decades. JAMA Oncol 6(3):350–357. https://doi.org/10.1001/jamaoncol.2019.5582
doi: 10.1001/jamaoncol.2019.5582
pubmed: 31895405
Aisyi M et al (2019) The effect of combination of steroid and L-asparaginase on hyperglycemia in children with acute lymphoblastic leukemia (ALL). APJCP 20(9):2619–2624. https://doi.org/10.31557/apjcp.2019.20.9.2619
doi: 10.31557/apjcp.2019.20.9.2619
pubmed: 31554355
pmcid: 6976823
Kowalczyk JR et al (2019) Long-term treatment results of polish pediatric and adolescent patients enrolled in the ALL IC-BFM 2002 trial. Am J Hematol 94(11):E307–e310. https://doi.org/10.1002/ajh.25619
doi: 10.1002/ajh.25619
pubmed: 31432528
pmcid: 6852109
Li C et al (2019) Long-term outcomes of modified BFM-95 regimen in adults with newly diagnosed standard-risk acute lymphoblastic leukemia: a retrospective single-center study. Int J Hematol 110(4):458–465. https://doi.org/10.1007/s12185-019-02703-0
doi: 10.1007/s12185-019-02703-0
pubmed: 31321731
Tantiworawit A et al (2019) Outcomes of adult acute lymphoblastic leukemia in the era of pediatric-inspired regimens: a single-center experience. Int J Hematol 110(3):295–305. https://doi.org/10.1007/s12185-019-02678-y
doi: 10.1007/s12185-019-02678-y
pubmed: 31161483
Distelhorst CW et al (1987) Neutrophil elastase produces 52-kD and 30-kD glucocorticoid receptor fragments in the cytosol of human leukemia cells. Blood 70(3):860–868
doi: 10.1182/blood.V70.3.860.860
Tissing WJ et al (2007) Genomewide identification of prednisolone-responsive genes in acute lymphoblastic leukemia cells. Blood 109(9):3929–3935
doi: 10.1182/blood-2006-11-056366
Tissing WJ et al (2005) Genetic variations in the glucocorticoid receptor gene are not related to glucocorticoid resistance in childhood acute lymphoblastic leukemia. Clin Cancer Res 11(16):6050–6056
doi: 10.1158/1078-0432.CCR-04-2097
Mousavian Z et al (2019) Differential network analysis and protein-protein interaction study reveals active protein modules in glucocorticoid resistance for infant acute lymphoblastic leukemia. Mol Med 25(1):36. https://doi.org/10.1186/s10020-019-0106-1
doi: 10.1186/s10020-019-0106-1
pubmed: 31370801
pmcid: 6676637
Lambrou GI et al (2020) Gene expression and resistance to glucocorticoid-induced apoptosis in acute lymphoblastic leukemia: a brief review and update. Curr Drug Res Rev 12(2):131–149. https://doi.org/10.2174/2589977512666200220122650
doi: 10.2174/2589977512666200220122650
pubmed: 32077838
Ghasemi A et al (2018) Evaluation of BAX and BCL-2 gene expression and apoptosis induction in acute lymphoblastic leukemia cell line CCRFCEM after high- dose prednisolone treatment. APJCP 19(8):2319–2323. https://doi.org/10.22034/apjcp.2018.19.8.2319
doi: 10.22034/apjcp.2018.19.8.2319
pubmed: 30141309
pmcid: 6171400
Marcopoulou CE et al (2003) Proliferative effect of growth factors TGF-beta1, PDGF-BB and rhBMP-2 on human gingival fibroblasts and periodontal ligament cells. J Int Acad Periodontol 5(3):63–70
pubmed: 12887144
Rocamora-Reverte L et al (2017) T-cell autonomous death induced by regeneration of inert glucocorticoid metabolites. Cell Death Dis 8(7):e2948. https://doi.org/10.1038/cddis.2017.344
doi: 10.1038/cddis.2017.344
pubmed: 28726773
pmcid: 5550885
McKay LI, Cidlowski JA (2000) CBP (CREB binding protein) integrates NF-kappaB (nuclear factor-kappaB) and glucocorticoid receptor physical interactions and antagonism. Mol Endocrinol 14(8):1222–1234
pubmed: 10935546
Pruett SB et al (2003) Characterization of glucocorticoid receptor translocation, cytoplasmic IkappaB, nuclear NFkappaB, and activation of NFkappaB in T lymphocytes exposed to stress-inducible concentrations of corticosterone in vivo. Int Immunopharmacol 3(1):1–16
doi: 10.1016/S1567-5769(02)00081-4
Almawi WY, Melemedjian OK (2002) Molecular mechanisms of glucocorticoid antiproliferative effects: antagonism of transcription factor activity by glucocorticoid receptor. J Leukoc Biol 71(1):9–15
pubmed: 11781376
Magnani M et al (2000) The ubiquitin-dependent proteolytic system and other potential targets for the modulation of nuclear factor-kB (NF-kB). Curr Drug Targets 1(4):387–399
doi: 10.2174/1389450003349056
Lambrou GI et al (2012) Glucocorticoid and proteasome inhibitor impact on the leukemic lymphoblast: multiple, diverse signals converging on a few key downstream regulators. Mol Cell Endocrinol 351(2):142–151. https://doi.org/10.1016/j.mce.2012.01.003
doi: 10.1016/j.mce.2012.01.003
pubmed: 22273806
Adamaki M et al (2017) Aberrant AML1 gene expression in the diagnosis of childhood leukemias not characterized by AML1-involved cytogenetic abnormalities. Tumour Biol 39(3):1010428317694308. https://doi.org/10.1177/1010428317694308
doi: 10.1177/1010428317694308
pubmed: 28349830
Adamaki M et al (2013) Implication of IRF4 aberrant gene expression in the acute leukemias of childhood. PLoS One 8(8):e72326. https://doi.org/10.1371/journal.pone.0072326
doi: 10.1371/journal.pone.0072326
pubmed: 23977280
pmcid: 3744475
Adamaki M et al (2015) HOXA9 and MEIS1 gene overexpression in the diagnosis of childhood acute leukemias: significant correlation with relapse and overall survival. Leuk Res 39(8):874–882. https://doi.org/10.1016/j.leukres.2015.04.012
doi: 10.1016/j.leukres.2015.04.012
pubmed: 26059450
Uzman BG et al (1966) Morphologic variations in human leukemic lymphoblasts (CCRF-CEM cells) after long-term culture and exposure to chemotherapeutic agents. A study with the electron microscope. Cancer 19(11):1725–1742. https://doi.org/10.1002/1097-0142(196611)19:11<1725::aid-cncr2820191142>3.0.co;2-t
doi: 10.1002/1097-0142(196611)19:11<1725::aid-cncr2820191142>3.0.co;2-t
pubmed: 5224274
Tindall EA et al (2007) Novel Plexor SNP genotyping technology: comparisons with TaqMan and homogenous MassEXTEND MALDI-TOF mass spectrometry. Hum Mutat 28(9):922–927
doi: 10.1002/humu.20533
Anderer G et al (2000) Polymorphisms within glutathione S-transferase genes and initial response to glucocorticoids in childhood acute lymphoblastic leukaemia. Pharmacogenetics 10(8):715–726
doi: 10.1097/00008571-200011000-00006
Zhang B et al (2005) WebGestalt: an integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res 33(Web Server issue):W741–W748. https://doi.org/10.1093/nar/gki475
doi: 10.1093/nar/gki475
pubmed: 15980575
pmcid: 1160236
Wang J et al (2013) WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013. Nucleic Acids Res 41(W1):W77–W83. https://doi.org/10.1093/nar/gkt439
doi: 10.1093/nar/gkt439
pubmed: 23703215
pmcid: 3692109
Wang J et al (2017) WebGestalt 2017: a more comprehensive, powerful, flexible and interactive gene set enrichment analysis toolkit. Nucleic Acids Res 45(W1):W130–W137. https://doi.org/10.1093/nar/gkx356
doi: 10.1093/nar/gkx356
pubmed: 28472511
pmcid: 5570149
Watson JV et al (1987) A pragmatic approach to the analysis of DNA histograms with a definable G1 peak. Cytometry 8(1):1–8
doi: 10.1002/cyto.990080101
Ormerod MG et al (1987) Improved program for the analysis of DNA histograms. Cytometry 8(6):637–641
doi: 10.1002/cyto.990080617
Abrams MT et al (2005) Evaluation of glucocorticoid sensitivity in 697 pre-B acute lymphoblastic leukemia cells after overexpression or silencing of MAP kinase phosphatase-1. J Cancer Res Clin Oncol 131(6):347–354
doi: 10.1007/s00432-004-0659-3
Abrams MT et al (2004) Inhibition of glucocorticoid-induced apoptosis by targeting the major splice variants of BIM mRNA with small interfering RNA and short hairpin RNA. J Biol Chem 279(53):55809–55817
doi: 10.1074/jbc.M411767200
Laane E et al (2007) Dexamethasone-induced apoptosis in acute lymphoblastic leukemia involves differential regulation of Bcl-2 family members. Haematologica 92(11):1460–1469
doi: 10.3324/haematol.10543
Dyczynski M et al (2018) Metabolic reprogramming of acute lymphoblastic leukemia cells in response to glucocorticoid treatment. Cell Death Dis 9(9):846. https://doi.org/10.1038/s41419-018-0625-7
doi: 10.1038/s41419-018-0625-7
pubmed: 30154400
pmcid: 6113325
Li Z et al (2019) The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells. Leukemia 33(1):262–266. https://doi.org/10.1038/s41375-018-0201-2
doi: 10.1038/s41375-018-0201-2
pubmed: 30008477
Seipel K et al (2019) Rationale for a combination therapy consisting of MCL1- and MEK-inhibitors in acute myeloid leukemia. Cancers 11(11):1179. https://doi.org/10.3390/cancers11111779
doi: 10.3390/cancers11111779
Inoue C et al (2020) Involvement of MCL1, c-myc, and cyclin D2 protein degradation in ponatinib-induced cytotoxicity against T315I(+) Ph+leukemia cells. Biochem Biophys Res Commun 525(4):1074–1080. https://doi.org/10.1016/j.bbrc.2020.02.165
doi: 10.1016/j.bbrc.2020.02.165
pubmed: 32184020
Aries IM et al (2013) The synergism of MCL1 and glycolysis on pediatric acute lymphoblastic leukemia cell survival and Prednisolone resistance. Haematologica 98(12):1905–1911. https://doi.org/10.3324/haematol.2013.093823
doi: 10.3324/haematol.2013.093823
pubmed: 24142999
pmcid: 3856966
Spijkers-Hagelstein JA et al (2014) Glucocorticoid sensitisation in Mixed Lineage Leukaemia-rearranged acute lymphoblastic leukaemia by the pan-BCL-2 family inhibitors gossypol and AT-101. Eur J Cancer 50(9):1665–1674. https://doi.org/10.1016/j.ejca.2014.03.011
doi: 10.1016/j.ejca.2014.03.011
pubmed: 24703900
Zhou F et al (2000) The delayed induction of c-jun in apoptotic human leukemic lymphoblasts is primarily transcriptional. J Steroid Biochem Mol Biol 75(2-3):91–99
doi: 10.1016/S0960-0760(00)00161-8